loading...| Preferred Name |
FP-1039 acts as a ligand-trap for FGFR2b-binding ligands in endometrial cancer |
|
| Synonyms |
|
|
| Definitions |
FP-1039 is a soluble fusion protein consisting of the extracellular region of FGFR1c bound to the Fc region of human IgG1. It is capable of binding to a wide range of FGF ligands and thereby prevents activation of multiple FGF receptors. FP-1039 is in Phase I clinical trials in solid malignancies and in Phase II trials for patients with endometrial cancers harbouring the activating mutations S252W and P253R (reviewed in Wesche, 2011). Edited: Rothfels, K, 2012-05-16 Authored: Rothfels, K, 2012-02-09 Reviewed: Ezzat, S, 2012-05-15 |
|
| ID |
http://purl.obolibrary.org/obo/HINO_0008129 |
|
| comment |
FP-1039 is a soluble fusion protein consisting of the extracellular region of FGFR1c bound to the Fc region of human IgG1. It is capable of binding to a wide range of FGF ligands and thereby prevents activation of multiple FGF receptors. FP-1039 is in Phase I clinical trials in solid malignancies and in Phase II trials for patients with endometrial cancers harbouring the activating mutations S252W and P253R (reviewed in Wesche, 2011). Edited: Rothfels, K, 2012-05-16 Authored: Rothfels, K, 2012-02-09 Reviewed: Ezzat, S, 2012-05-15 |
|
| definition source |
Reactome, http://www.reactome.org Pubmed21711248 |
|
| has input | ||
| has output | ||
| label |
FP-1039 acts as a ligand-trap for FGFR2b-binding ligands in endometrial cancer |
|
| prefixIRI |
HINO:0008129 |
|
| prefLabel |
FP-1039 acts as a ligand-trap for FGFR2b-binding ligands in endometrial cancer |
|
| seeAlso |
Reactome Database ID Release 432077421 ReactomeREACT_121035 |
|
| subClassOf |